Suchergebnisse - "Ewer, Katie J"

PubPharm (96)

1

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children : a multicentre, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2024

von Datoo, M. | Dicko, A. | Tinto, H. | +117

2

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine : a mathematical modelling study

enthalten in: The Lancet. Infectious diseases | 2024

von Schmit, N. | Topazian, H. | Natama, H. | +26

3

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults : an open-label, non-randomised, first-in-human phase 1 clinical trial

enthalten in: The Lancet. Infectious diseases | 2023

von Jenkin, D. | Wright, D. | Folegatti, P. | +16

CommentIn: Lancet Infect Dis. 2023 Aug;23(8):887-889. - PMID 37060918

4

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222) : 1 year of follow-up of two randomized controlled trials

enthalten in: Clinical and experimental immunology | 2023

von Voysey, M. | Flaxman, A. | Aboagye, J. | +34

5

Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies

enthalten in: PloS one | 2023

von Mugo, R. | Orindi, B. | Shee, F. | +5

6

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

enthalten in: bioRxiv.org | 2023

von Ogbe, A. | Pace, M. | Bittaye, M. | +56

7

A tool for evaluating heterogeneity in avidity of polyclonal antibodies

enthalten in: Frontiers in immunology | 2023

von Li, K. | Dodds, M. | Spreng, R. | +15

8

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso : a phase 1/2b randomised controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Datoo, M. | Natama, H. | Somé, A. | +30

CommentIn: Lancet Infect Dis. 2022 Dec;22(12):1655-1656. - PMID 36087589

9

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine : An open-label partially-randomised ascending dose phase I trial

enthalten in: EBioMedicine | 2022

von Madhavan, M. | Ritchie, A. | Aboagye, J. | +19

10

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

enthalten in: JCI insight | 2022

von Ogbe, A. | Pace, M. | Bittaye, M. | +55

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]